Hikma Pharmaceuticals (LON:HIK) Reaches New 1-Year Low - What's Next?

Key Points

• Hikma Pharmaceuticals' shares have dropped to a new 52-week low of GBX 1,592 ($21.41), reflecting a decline in the stock's performance amid trading.
• Multiple research firms have downgraded Hikma's price targets, with JPMorgan Chase & Co. lowering theirs from GBX 2,600 to GBX 2,500.
• Insiders have shown confidence in the company, acquiring a total of 217,500 shares over the last 90 days, indicating potential belief in a future rebound.

Hikma Pharmaceuticals PLC (LON:HIK - Get Free Report) shares hit a new 52-week low during trading on Thursday . The company traded as low as GBX 1,592 ($21.41) and last traded at GBX 1,592 ($21.41), with a volume of 368090 shares trading hands. The stock had previously closed at GBX 1,613 ($21.69).

Analyst Upgrades and Downgrades

A number of research firms have recently commented on HIK. JPMorgan Chase & Co. reduced their price objective on shares of Hikma Pharmaceuticals from GBX 2,600 to GBX 2,500 and set an "overweight" rating for the company in a report on Friday, August 8th. Jefferies Financial Group reaffirmed a "buy" rating and set a GBX 2,600 price target on shares of Hikma Pharmaceuticals in a research note on Thursday, August 7th. Finally, Deutsche Bank Aktiengesellschaft lowered their price objective on Hikma Pharmaceuticals from GBX 3,100 to GBX 2,850 and set a "buy" rating for the company in a research report on Tuesday, August 12th. Four research analysts have rated the stock with a Buy rating, According to MarketBeat.com, Hikma Pharmaceuticals has an average rating of "Buy" and a consensus price target of GBX 2,627.50.

Hikma Pharmaceuticals Stock Down 1.3%

The company has a quick ratio of 1.27, a current ratio of 1.66 and a debt-to-equity ratio of 55.82. The stock has a 50 day simple moving average of GBX 1,804.47 and a 200 day simple moving average of GBX 1,933.68. The stock has a market cap of £3.53 billion, a price-to-earnings ratio of 953.29, a PEG ratio of 2.38 and a beta of 0.41.

Insider Buying and Selling at Hikma Pharmaceuticals

In related news, insider Laura Balan Balan acquired 3,500 shares of the firm's stock in a transaction that occurred on Friday, August 22nd. The shares were bought at an average cost of GBX 1,821 per share, for a total transaction of £63,735. Also, insider Mazen Darwazah bought 14,000 shares of Hikma Pharmaceuticals stock in a transaction that occurred on Tuesday, September 16th. The shares were acquired at an average price of GBX 1,603 per share, with a total value of £224,420. Over the last 90 days, insiders acquired 217,500 shares of company stock worth $380,015,500. Corporate insiders own 17.76% of the company's stock.

About Hikma Pharmaceuticals

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.